Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Efficacy and safety of early initiation of sodium–glucose cotransporter 2 inhibitors in acute heart failure: a systematic review and meta-analysis
Session:
Prémio Jovem Investigador
Speaker:
Bernardo Lisboa Resende
Congress:
CPC 2026
Topic:
D. Heart Failure
Theme:
11. Acute Heart Failure
Subtheme:
11.4 Acute Heart Failure– Treatment
Session Type:
Sessão de Prémios
FP Number:
---
Authors:
Bernardo Resende; Emídio Mata; Ana Marta Pinto; Margarida Castro; Tomás Carlos; Luísa Rocha; Miguel Vicente; João Português; Sílvia Ribeiro; João Gameiro; António Lourenço; Lino Gonçalves
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:11.0pt">Background:</span></strong><span style="font-size:11.0pt"> Acute heart failure (AHF) remains associated with high short-term mortality and rehospitalization despite advances in therapy. Sodium–glucose cotransporter2 inhibitors (SGLT2i) provide robust cardiovascular benefits in heart failure, but their efficacy and safety when initiated during AHF hospitalization are less well established. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:11.0pt">Methods:</span></strong><span style="font-size:11.0pt"> Following a systematic search of five databases, a systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of the initiation of dapagliflozin or empagliflozin during hospitalization for AHF, in addition to standard therapy. Primary outcomes were all-cause mortality and heart failure hospitalization (HFH). Secondary outcomes included all-cause mortality at 1-month, cardiovascular death, serious adverse events leading to drug discontinuation, acute kidney injury (AKI), hypotension, hypoglycemia, and diabetic ketoacidosis. Data were pooled using inverse variance random-effects models. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:11.0pt">Results:</span></strong><span style="font-size:11.0pt"> Eight RCTs including 3596 patients (1817 SGLT2i; 1779 control) were analyzed. SGLT2i initiation in AHF significantly reduced all-cause mortality (RR 0.63, 95% CI 0.46–0.85; P = 0.003; I² = 0%). No significant reduction was observed for HFH (RR 0.86, 95% CI 0.69–1.07; P = 0.78; I² = 0%). All-cause mortality at 1 month and cardiovascular death, did not differ significantly between groups. Pooled analyses showed no excess risk of hypotension, hypoglycemia, AKI or ketoacidosis. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:11.0pt">Conclusion:</span></strong><span style="font-size:11.0pt"> Initiation of SGLT2i during AHF hospitalization significantly improves survival without increasing adverse safety events, supporting their use as an early adjunct to guideline-directed therapy. The absence of a clear effect on rehospitalization highlights the need for further large-scale and patient-level analyses.</span></span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site